Breather Trainer Versus Pulmonary Rehabilitation on Cardiopulmonary Efficiency

NCT ID: NCT05382780

Last Updated: 2022-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2022-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the difference between The Breather respiratory muscle trainer and pulmonary rehabilitation in patients with COPD post COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main concern in post COVID-19 patients is the involvement of respiratory system and cardiovascular system which may result in dyspnea, low blood oxygen saturation, and decrease cardiopulmonary efficiency.

In cases of post COVID-19 patients with COPD their state is deconditioned and more critical than normal to be either in the zone of progression or regression or stability as the studies showed that handling of these cases during (3-6 months post-COVID) will prevent these symptoms from becoming permanent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The breather respiratory muscle trainer group

40 patients (20 males and 20 females) will receive The breather respiratory muscle trainer for 30 minutes and mild interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks.

Group Type EXPERIMENTAL

The breather respiratory muscle trainer

Intervention Type OTHER

The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.

interval aerobic training and respiratory training

Intervention Type OTHER

mild intensity interval aerobic training and respiratory training on treadmill

Diaphragmatic and localized breathing exercises group

40 patients (20 males and 20 females) will receive diaphragmatic and localized breathing exercises ( especially Middle \& Lower segments) and mild intensity interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks,

Group Type EXPERIMENTAL

Diaphragmatic and localized breathing exercises

Intervention Type OTHER

A. Diaphragmatic breathing exercises:

Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.

B. Localized Breathing:

Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.

C. Mild Interval training exercise

interval aerobic training and respiratory training

Intervention Type OTHER

mild intensity interval aerobic training and respiratory training on treadmill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The breather respiratory muscle trainer

The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.

Intervention Type OTHER

Diaphragmatic and localized breathing exercises

A. Diaphragmatic breathing exercises:

Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.

B. Localized Breathing:

Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.

C. Mild Interval training exercise

Intervention Type OTHER

interval aerobic training and respiratory training

mild intensity interval aerobic training and respiratory training on treadmill

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. SPO2 ≥ 93%
2. Their age ranges from 30-40 years old.
3. COPD patients GOLD1 (Mild FEV1≥80% predicted) and GOLD2 (Moderate 50% ≤FEV1\<80%predicted) (Manian, 2019)
4. patients diagnosed as post COVID-19 Pneumonia between 3 and 6 Months ago with CT scan and PCR testing.
5. Their body mass index (BMI) ranged from 20 to 29.9kg/m2.
6. Stable medical cases with dyspnea

Exclusion Criteria

Patients who will meet one of the following criteria will be excluded from the study:

1. patients with cardiac problems e.g. atrial fibrillation, left bundle-branch block, heart failure.
2. Sever cases of COPD (FEV1/FVC\< 50%)
3. Mitral or aortic valvular disease, pericardial effusion.
4. Recent myocardial infarction.
Minimum Eligible Age

30 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Horus University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eman Rashad Ali Elsayed

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eman Rashad, Assistant lecturer

Role: PRINCIPAL_INVESTIGATOR

Horus University in Egypt

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Outpatient clinic, Faculty of Physical Therapy, Horus University, Egypt

Damietta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eman Rashad, Assistant lecturer

Role: CONTACT

+201011431165

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Eman_Rashad_PhD_2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COPD Circuit Exercise
NCT05395390 COMPLETED NA